期刊论文详细信息
Biology of Sex Differences
Age- and sex-specific differences in blood-borne microvesicles from apparently healthy humans
Callie M Gustafson1  Alex J Shepherd1  Virginia M Miller2  Muthuvel Jayachandran2 
[1] Department of Surgery, Mayo Clinic, 200 First St. SW, Rochester 55905, MN, USA
[2] Physiology and Biomedical Engineering, Mayo Clinic, 200 First St. SW, Rochester 55905, MN, USA
关键词: Sex differences;    Procoagulant vesicles;    Microparticles;    Flow cytometry;    Extracellular vesicles;    Anticoagulant vesicles;   
Others  :  1180487
DOI  :  10.1186/s13293-015-0028-8
 received in 2014-12-03, accepted in 2015-04-19,  发布年份 2015
PDF
【 摘 要 】

Background

Sex differences in incidence of cardiovascular disease may reflect age-associated intravascular cellular activation resulting in shedding of cell membrane-derived bioactive microvesicles (MV or microparticles) into the blood. Concentrations of cell-specific MV in blood have the potential to be a diagnostic/prognostic marker of pathology, but ranges of MV must first be established in healthy individuals. This study identified cellular origin of blood-borne MV >0.2 μm in blood of apparently healthy women and men aged from 20–70 years.

Methods

Venous blood from apparently healthy participants in the Mayo Clinic Biobank was collected into tubes containing protease inhibitors as the anticoagulant. MV were isolated by standardized differential centrifugation and characterized by digital flow cytometer. Each cellular origin of MV was verified by two different antibodies with strong correlation between the two distinct antibodies (e.g., for platelet-derived MV, r2 = 0.97).

Results

MV derived from platelets were the most abundant type of MV in blood from women and men in all age groups. Total numbers of phosphatidylserine, P-selectin, and platelet- and endothelium-derived MV were significantly (P < 0.05) greater in women than men. Numbers of MV from erythrocytes and stem/progenitor cells were significantly lower in premenopausal women than age-matched men. Number of tissue factor pathway inhibitor positive MV were significantly (P < 0.05) lower whereas erythrocyte-derived MV were significantly higher in postmenopausal women compared to premenopausal women. In women, there was a positive relationship between age and erythrocyte-derived MV (ρ = 0.28; P = 0.009), while in men adipocyte-derived MV increased with age (ρ = 0.33; P = 0.01).

Conclusions

This study provides ranges for cellular origin of blood-borne MV in age-matched, apparently healthy women and men from which to compare diagnostic and prognostic uses of blood-borne MV in larger studies and patient population. In addition, sex- and age-specific differences in phosphatidylserine, platelet-, endothelium-, erythrocyte-, and adipocyte-derived blood-borne MV may contribute to differential progression of cardiovascular disease in women compared to men.

【 授权许可】

   
2015 Gustafson et al.; licensee BioMed Central.

【 预 览 】
附件列表
Files Size Format View
20150513003923516.pdf 838KB PDF download
Figure 3. 31KB Image download
Figure 2. 29KB Image download
Figure 1. 51KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】
  • [1]Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009; 101:439-51.
  • [2]Zhu H, Fan GC. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis. 2011; 1:138-49.
  • [3]VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res. 2003; 59:277-87.
  • [4]Tushuizen ME, Diamant M, Sturk A, Nieuwland R. Cell-derived microparticles in the pathogenesis of cardiovascular disease: friend or foe? Arterioscler Thromb Vasc Biol. 2011; 31:4-9.
  • [5]Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009; 19:43-51.
  • [6]Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res. 2014; 114:345-53.
  • [7]Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007; 21:157-71.
  • [8]Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol. 2007; 137:36-48.
  • [9]Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001; 85:639-46.
  • [10]Jayachandran M, Litwiller RD, Owen WG, Heit JA, Behrenbeck TR, Mulvagh SL et al.. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol. 2008; 295:931-8.
  • [11]Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F et al.. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol. 2006; 26:2594-604.
  • [12]Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al.. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014; 129:e28-292.
  • [13]Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A et al.. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011; 165:687-701.
  • [14]Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011; 97:870-5.
  • [15]Rylance PB, Brincat M, Lafferty K, De Trafford JC, Brincat S, Parsons V et al.. Natural progesterone and antihypertensive action. Br Med J. 1985; 290:13-4.
  • [16]Barbagallo M, Dominguez LJ, Licata G, Shan J, Bing L, Karpinski E et al.. Vascular effects of progesterone: role of cellular calcium regulation. Hypertension. 2001; 37:142-7.
  • [17]Lee WS, Harder JA, Yoshizumi M, Lee ME, Haber E. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med. 1997; 3:1005-8.
  • [18]Nilsson BO. Modulation of the inflammatory response by estrogens with focus on the endothelium and its interactions with leukocytes. Inflamm Res. 2007; 56:269-73.
  • [19]Villablanca AC, Jayachandran M, Banka C. Atherosclerosis and sex hormones: current concepts. Clin Sci. 2010; 119:493-513.
  • [20]Miller VM, Garovic VD, Kantarci K, Barnes JN, Jayachandran M, Mielke MM et al.. Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause. Biol Sex Differ. 2013; 4:6. BioMed Central Full Text
  • [21]Jayachandran M, Litwiller RD, Lahr BD, Bailey KR, Owen WG, Mulvagh SL et al.. Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk. J Cardiovasc Transl Res. 2011; 4:811-22.
  • [22]Jayachandran M, Litwiller RD, Owen WG, Miller VM. Circulating microparticles and endogenous estrogen in newly menopausal women. Climacteric. 2009; 12:177-84.
  • [23]Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al.. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10:1470-6.
  • [24]Julich H, Willms A, Lukacs-Kornek V, Kornek M. Extracellular vesicle profiling and their use as potential disease specific biomarker. Front Immunol. 2014; 5:413.
  • [25]Buzas EI, Gyorgy B, Nagy G, Falus A, Gay S. Emerging role of extracellular vesicles in inflammatory diseases. Nat Rev Rheumatol. 2014; 10:356-64.
  • [26]Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol. 1999; 30:111-42.
  • [27]Leroyer AS, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z et al.. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol. 2007; 49:772-7.
  • [28]Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A et al.. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001; 104:2649-52.
  • [29]Jayachandran M, Miller VM, Heit JA, Owen WG. Methodology for isolation, identification and characterization of microvesicles in peripheral blood. J Immunol Methods. 2012; 375:207-14.
  • [30]Olson JE, Ryu E, Johnson KJ, Koenig BA, Maschke KJ, Morrisette JA et al.. The Mayo Clinic Biobank: a building block for individualized medicine. Mayo Clin Proc. 2013; 88:952-62.
  • [31]Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR et al.. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005; 8:3-12.
  • [32]Jayachandran M, Preston CC, Hunter LW, Jahangir A, Owen WG, Korach KS et al.. Loss of estrogen receptor ß decreases mitochondrial energetic potential and increases thrombogenicity of platelets in aged female mice. Age. 2010; 32:109-21.
  • [33]Jayachandran M, Lugo G, Heiling H, Miller VM, Rule AD, Lieske JC. Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study. Biol Sex Differ. 2015; 6:2. BioMed Central Full Text
  • [34]Toth B, Nikolajek K, Rank A, Nieuwland R, Lohse P, Pihusch V et al.. Gender-specific and menstrual cycle dependent differences in circulating microparticles. Platelets. 2007; 18:515-21.
  • [35]Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A et al.. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005; 353:999-1007.
  • [36]Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U et al.. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005; 111:2981-7.
  • [37]Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L et al.. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood. 2007; 110:2440-8.
  • [38]Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res. 2010; 38:215-24.
  • [39]Danielson KM, Das S. Extracellular vesicles in heart disease: excitement for the future? Exosomes Microvesicles. 2014.
  • [40]Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al.. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995; 92:9363-7.
  • [41]Chimenti C, Kajstura J, Torella D, Urbanek K, Heleniak H, Colussi C et al.. Senescence and death of primitive cells and myocytes lead to premature cardiac aging and heart failure. Circ Res. 2003; 93:604-13.
  • [42]Bosman GJ, Lasonder E, Groenen-Dopp YA, Willekens FL, Werre JM, Novotny VM. Comparative proteomics of erythrocyte aging in vivo and in vitro. J Proteomics. 2010; 73:396-402.
  • [43]Bosman GJ, Lasonder E, Groenen-Dopp YA, Willekens FL, Werre JM. The proteome of erythrocyte-derived microparticles from plasma: new clues for erythrocyte aging and vesiculation. J Proteomics. 2012; 76:203-10.
  • [44]Willekens FL, Werre JM, Kruijt JK, Roerdinkholder-Stoelwinder B, Groenen-Dopp YA, van den Bos AG et al.. Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors. Blood. 2005; 105:2141-5.
  • [45]Muller G. Microvesicles/exosomes as potential novel biomarkers of metabolic diseases. Diabetes Metab Syndr Obes. 2012; 5:247-82.
  • [46]Aoki N, Yokoyama R, Asai N, Ohki M, Ohki Y, Kusubata K et al.. Adipocyte-derived microvesicles are associated with multiple angiogenic factors and induce angiogenesis in vivo and in vitro. Endocrinology. 2010; 151:2567-76.
  • [47]Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008; 29:2959-71.
  • [48]Nicklas BJ, Penninx BW, Cesari M, Kritchevsky SB, Newman AB, Kanaya AM et al.. Association of visceral adipose tissue with incident myocardial infarction in older men and women: the Health, Aging and Body Composition Study. Am J Epidemiol. 2004; 160:741-9.
  • [49]Kanhai DA, Kappelle LJ, van der Graaf Y, Uiterwaal CS, Visseren FL. The risk of general and abdominal adiposity in the occurrence of new vascular events and mortality in patients with various manifestations of vascular disease. Int J Obes. 2012; 36:695-702.
  • [50]Kranendonk ME, de Kleijn DP, Kalkhoven E, Kanhai DA, Uiterwaal CS, van der Graaf Y et al.. Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease. Cardiovasc Diabetol. 2014; 13:37. BioMed Central Full Text
  • [51]Lemieux S, Prud’homme D, Bouchard C, Tremblay A, Despres JP. Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr. 1993; 58:463-7.
  文献评价指标  
  下载次数:47次 浏览次数:20次